Platelet-rich plasma
Autologous PRP options are considered for appropriate wounds as part of a documented wound-bed and tissue-repair strategy.
Advanced wound care at CWS brings PRP, regenerative peptides (BPC-157 and TB-500), UltraMIST non-contact ultrasound, and adipose-derived biologics that turn a patient’s own fat into regenerative material into the same practice that manages virtual evaluation, clinic procedures, tele-wound follow-up, and surgical intervention when appropriate.
When a wound stalls, advanced treatment is selected inside the same evaluation-first pathway. CWS evaluates the wound, chooses the appropriate treatment layer, and keeps the same clinical team responsible through closure.
Autologous PRP options are considered for appropriate wounds as part of a documented wound-bed and tissue-repair strategy.
Physician-directed peptide therapy, including BPC-157 and TB-500, is reviewed case by case to support tissue repair, with eligibility, sourcing, safety, and compliance handled before any treatment decision.
Non-contact low-frequency ultrasound therapy (UltraMIST) supports wound-bed preparation, biofilm disruption, and the timing of biologic or procedural escalation.
Adipose-derived biologics turn a patient’s own fat into regenerative material, selected alongside skin substitutes around wound type, vascular supply, infection status, and documentation requirements.
Some advanced wound-care procedures may be covered by Medicare, Medicaid, or commercial plans when medical-necessity and documentation criteria are met. Coverage varies by diagnosis, product, plan, and prior authorization requirements. Inquire before scheduling so the team can review eligibility.
The RegenWound Protocol is the CWS care sequence for wounds that need more than dressings: evaluation, wound-bed preparation, regenerative treatment selection, tele-wound follow-up, and surgical intervention when appropriate.
Assess perfusion, infection risk, depth, drainage, prior therapies, and the reason the wound has stalled.
Select PRP, regenerative peptides (BPC-157, TB-500), UltraMIST ultrasound, or adipose-derived biologics when clinically appropriate.
Tele-wound check-ins, clinic procedures, and surgical escalation remain connected to the same team, with notes back to the existing care team at every step.
Advanced wound-care procedures are positioned inside the larger limb-preservation continuum: treat infection earlier, reduce avoidable amputation risk, and escalate before a salvageable limb is lost.
Regenerative care is paired with debridement, biologics, structural correction, and OR access when a limb is still salvageable.
Earlier escalation, coordinated follow-up, and surgical access help prevent wounds from drifting into emergency infection pathways.
The same clinical team owns the case from first assessment through advanced treatment, surgical escalation, and closure.
Send the diagnosis, wound location, duration, prior therapies, and current insurance. We will review whether an advanced wound-care pathway makes sense.